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Kyoji Okita1*, Akihiro Shiina1,2, Michiko Nakazato1,3 and Masaomi Iyo1,2Abstract
This case report details the therapeutic effects of tandospirone on two patients with anorexia nervosa, one with the
restricting subtype (ANR), and another with the binge-eating/purging subtype (ANBP). A 22-year-old female patient
with ANR and a 23-year-old female patient with ANBP were treated successfully with the 5-HT1A partial agonist
tandospirone. After treatment, not only did both patients gain weight, they also showed improved scores on the
Eating Disorder Examination Questionnaire. In addition, a 6-month follow-up showed maintenance of these effects.
In this disorder, tandospirone may be an effective drug for long-term use with good patient compliance.
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Eating disorders such as anorexia nervosa (AN) have a
relatively high incidence in women and the highest mor-
tality rate among mental disorders [1]. Patients suffering
from AN show characteristic symptoms, typified by an in-
tense fear of gaining weight or becoming fat, body image
distortion, and eating concerns. They are distressed by
their obsessive psychopathology. Even when their body
mass index falls below minimum levels, they still report
feeling larger than they actually are and maintain their fear
of gaining weight. Although they have a keen interest in
eating, they often restrict calorie consumption and/or
vomit after binge eating. In addition, despite significant
physical symptoms, patients tend to be in self-denial about
the seriousness of their disease. Attempts to treat this
disease are confounded by patients frequently presenting
with physical problems, such as heart failure, increased
susceptibility to infection, and osteoporosis.
There are currently no definitively effective treatments
for AN, and although various medications including select-
ive serotonin reuptake inhibitors (SSRIs) or antipsychotics
have been evaluated in the past, there is little evidence to
support the benefit of psychotropic medication for AN
treatment [2]. One reason for this lack of evidence is that
robust, randomized, placebo-controlled studies are difficult* Correspondence: okitak@graduate.chiba-u.jp
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reproduction in any medium, provided the orto perform due to high dropout rates [3]. This lack of com-
pliance may be due to denial about their disease as well as
a continued fear of gaining weight. Treatments that target
the fear of gaining weight and body image distortion seem
to be more acceptable to AN patients and therefore more
effective than treatments that solely target weight gain.
This is a pivotal issue for consideration in the prevention
of relapse and aggravation of symptoms [4].
There are several biological hypotheses about AN that
highlight a relationship between disease pathology and
serotonin [5]. Neuroimaging studies (e.g., positron emis-
sion tomography and single photon emission tomog-
raphy) have identified a role for the 5-HT1A receptor,
and it is already known that upregulated expression of
this receptor in various areas of the brain is associated
with anxiety [6].
This report aims to show the effects of the 5-HT1A
partial agonist tandospirone in the treatment of AN. Both
cases showed weight gain in a relatively short time period
and improvement in the Eating Disorder Examination
Questionnaire (EDE-Q) [7], which is a self-report ques-
tionnaire useful for determining the effect of treatment
and providing a comprehensive assessment of the beha-
vioral and psychological parameters characteristic of the
disorder. The EDE-Q generates four subscales (restraint,
eating concern, weight concern, and shape concern) as
well as a global score. Higher scores indicate a greater
severity of eating disorder psychopathology.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Case A
Patient A is a 23-year-old married female with one child.
After her husband had an affair with a thinner woman,
she decided to lose weight. Subsequent to this, she
began to experience nausea and palpitations on eating.
Before these symptoms developed, she weighed approxi-
mately 50 kg, with a body mass index (BMI) of 20.6.
Within 5 months, she weighed 41 kg and was amenor-
rheic. Her eating patterns were severely restricted to one
meal between morning and noon per day.
She presented at our clinic complaining of noncausal
nausea and weight loss. At her first visit, she measured
158-cm tall and weighed 41.3 kg, with a BMI of 16.5. At
this point, she had already lost 8 kg and had not had
menses for almost 4 months. Although she admitted
that she had lost weight, she felt that she still looked the
same and expressed a desire to reduce her weight
further to 30 kg. She also complained about a fear of
gaining weight. She was diagnosed in accordance with
DSM-IV-TR as having AN of restricted type (ANR).
She was prescribed 1 mg of ethyl lofrazepate to com-
bat her anxiety attacks and palpitations. While this
symptom showed small improvement, she maintained
her fear of weight gain and eating patterns and showed
further weight loss from 41.3 to 40 kg (BMI 16.4). At a
weight of 40.0 kg, her EDE-Q subscales of restricting/
eating concern/weight concern/shape concern and glo-
bal scores were 4.6/1.6/3.6/4.88 and 3.67, respectively.
She was started on tandospirone because of its fewer
side effects on the digestive system relative to SSRIs and
its antianxiety effects. Patient A was scheduled for two
weekly visits to our clinic to monitor side effects, al-
though no specific psychological treatment was pro-
vided. At these visits and in the absence of side effects,
tandospirone was initiated at 20 mg and escalated by 20
mg every 2 weeks until it reached 60 mg. It was
recommended that she take tandospirone twice daily
(when prescribed 20 and 40 mg) or three times daily
(when prescribed 60 mg). From the onset of treatment,
our patient’s dietary intake gradually increased, and
she began to gain weight. In addition, she no longer
complained about feelings of fear and guilt. Four weeks
into therapy, her weight had increased to 43 kg (BMI
17.7), and her EDE-Q scores reduced, with the subscale
scores of restricting/eating concern/weight concern/
shape concern and global score being 3.4/0.6/1.2/4.0 and
2.3, respectively. After approximately 20 weeks, her
menses resumed. At the 6-month point, she was still
adhering to her treatment regime, her EDE-Q diagnostic
score was 6, and the subscales restricting/eating con-
cern/weight concern/shape concern and global score
were 1.2/0/2.0/3.0 and 1.55, respectively. Also, she had
gained weight to reach 45.0 kg with a BMI of 18.5.Case B
Patient B is a 22-year-old female. She began to restrict
her eating after gaining 20 kg during pregnancy. Soon
after this, she drank only water during the day and over-
ate and purged in the evening. Within 6 months, she be-
came amenorrheic.
She presented at our hospital seeking help to curb her
binge eating and purging. She was in a pattern of binge
eating and purging twice in a day. She felt depressed and
irritated that she was not in a good physical condition
and unable to be a good parent. At the first visit, she
measured 153-cm tall, weighed 35.0 kg, and had a BMI
of 15.0. Although she had already experienced a 13-kg
weight loss and almost 10 months of amenorrhea, she
displayed body image distortion saying ‘If I lose more
weight, I will be fine.’ Additionally she stated ‘I feel more
confident when losing weight.’ It was clear that her
self-esteem was tightly linked to her weight. She was di-
agnosed according to DSM-IV-TR with AN of binge/
purging type (ANBP).
First, she was prescribed 1 mg of ethyl lofrazepate to
improve her irritability. This proved effective for her in-
somnia, but her purging habits gradually deteriorated,
and she began cathartic abuse. As a result, her weight
fell to 34.8 kg (BMI 14.9). At this weight, the EDE-Q
subscales of restricting/eating concern/weight concern/
shape concern and global score were 2.4/4.4/4.2/5.25
and 4.06, respectively. Tandospirone was started at 20
mg and escalated by 20 mg at 2-week intervals until it
reached 60 mg, as in case A. Four weeks after the initi-
ation of tandospirone, she felt an improvement in her de-
pressive mood, and her weight increased to 36.3 kg (BMI
15.4). At this time, the EDE-Q subscales of restricting/eat-
ing concern/weight concern/shape concern and global
score were 2.4/2.2/0.2/1.75 and 1.64, respectively. Al-
though her binge eating and purging continued, she
stopped cathartic abuse 3 months into treatment and re-
duced her binge eating and purging to once a day. Her
weight increased further to 39.0 kg (BMI 16.7) by week
24, and her EDE-Q subscales of restricting/eating con-
cern/weight concern/shape concern and global score were
2.4/2.0/0.6/3.5 and 2.13, respectively. Shape concern and
weight concern subscale scores increased compared to
those obtained in week 4. This is thought to be due to the
subject being in a bad mood after a patient commented
that she looked fatter.
Discussion
To the best of our best knowledge, this is the first case
report showing a therapeutic effect of tandospirone in
treating AN of both the restricting and binge/purging
types. In the USA and Europe, an equivalent 5-HT1A re-
ceptor partial agonist, buspirone, is available on the mar-
ket, but its effect in treating AN is unknown.
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and single photon emission computed tomography with
5-HT-specific radioligands have consistently shown 5-
HT1A transporter alterations in AN patients within the
cortical and limbic structures, which may be related to
behavioral inhibition and body image distortions [5].
Tandospirone mediates two important effects that are
integral to alleviating the symptoms of AN. First,
tandospirone induces improvement not only in weight
gain but also in EDE-Q scores, suggesting improved psy-
chopathology of the patient towards their disorder
(Table 1). Disease psychopathology is a core and
treatment-refractive symptom of AN. Patients have a
morbid fear of weight gain and body image distortion.
Treatments that target this core symptom are more
likely to be effective in terms of patient compliance and
thus prevention of relapse and aggravation of symptoms,
compared with treatments that only target weight gain.
In these two cases, only psychotropic medication was
administered, and no AN-specific psychotherapy was
performed. We found that tandospirone improved EDE-
Q scoring in both patients. Significant improvements
were seen in shape concern and global scores, when
comparing week 0 with week 24, using t test (Table 1).
After treatment, patient A was able to eat an additional
afternoon meal, while patient B stopped her cathartic
abuse and reduced her binge and purge behavior to once
a day. As mentioned above, PET studies have shown that
5-HT1A receptors are highly expressed in specific areas
of the brain in patients with AN. This high expression in
the dorsal raphe leads to a deterioration of serotonin
neuron activity, resulting in a decrease of extracellular
serotonin [8]. Tandospirone is a selective agonist of the
5-HT1A receptor [9], and it is thought to desensitize
presynaptic 5-HT1A autoreceptors on dendrites of sero-
tonin neurons in the dorsal raphe and thus normalize




BMI 16.4 17.7 18.5
Height 156 156 156
Weight 40.0 43.0 45.0
EDE-Q
Restricting subscale 4.6 3.4 1.2
Eating concern subscale 1.6 0.6 0.0
Weight concern subscale 3.6 1.2 2.0
Shape concern subscale 4.88 4.0 3.0
Global score 3.67 2.3 1.55
aPaired Student’s t test, two-tailed alpha level of 0.05 at 0 week versus 24 week. *pthat tandospirone may act directly on the 5-HT1A
autoreceptor to improve the psychopathology seen
in AN.
Secondly, tandospirone treatment has a low incidence
of side effects. Patients with AN often also suffer from a
range of physical problems, such as loss of bone mass or
severe obstipation, as a consequence of being in a per-
sistent state of subnutrition. Therefore, the low inci-
dence of side effects, particularly digestive symptoms
that interfere with eating or hypnesthesia that may in-
crease the risk of falls, does not add to the patient’s bur-
den. Pharmacologically, tandospirone has a much lower
frequency of side effects than the majorly prescribed
SSRIs or antipsychotics used in Japan [11-15]. Anti-
psychotic medication has been proven useful in treating
AN [16], but the duration of these studies is relatively
short, and the efficacy for relapse prevention in the long
term is not proven. In addition, the associated weight
gain induced by these drugs leads to high levels of pa-
tient noncompliance. To date, there is no evidence that
tandospirone induces weight gain. These combined fac-
tors make tandospirone an attractive drug for long-term
use, with high compliance in this cohort of patients.
This study is by no means conclusive. The relapse rate
of AN is very high, and in this study, our patients were
followed up for 6 months. This time frame may need to be
extended in order to evaluate the effect of recurrence pre-
vention with this drug. Further, controlled trials in AN are
needed to fully explore the effects of tandospirone in
clinical practice.
Conclusion
We report cases of patients with ANR and ANBP who
were successfully treated with 5-HT1A partial agonist
tandospirone. Tandospirone may be an effective drug for
long-term use with good patient compliance due to its
pharmacological characteristics.administering tandospirone
tandospirone (weeks) p valuea
Case B
0 4 24
14.9 15.4 16.7 *p = 0.049
153 153 153
34.8 36.3 39.0
2.4 2.4 2.4 p = 0.500
4.4 2.2 2.0 p = 0.126
4.2 0.2 0.6 p = 0.234
5.25 1.75 3.5 *p = 0.023
4.06 1.64 2.13 *p = 0.028
< 0.05.
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